Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study - The Lancet Infectious Diseases
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial - The Lancet Infectious Diseases
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression - The Lancet Infectious Diseases
Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil - The Lancet
Collaborative Research: Community Health Impact Coalition Lancet Preprint - Research - Community Health Toolkit
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial - The Lancet Regional Health – Americas
Robustness of evidence reported in preprints during peer review - The Lancet Global Health
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial - The Lancet
Preprints and Preprint Server Update - Science Editor
Elsevier: Preprints With The Lancet Launches on SSRN
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study - The Lancet
Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis - The Lancet Global Health
Retracted coronavirus (COVID-19) papers – Retraction Watch
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system - The Lancet Infectious Diseases
eBioMedicine Home Page
Preprints with The Lancet: joining online research discussion platforms - The Lancet
The Lancet on X: "NEW—Most reliable estimates to date suggest 1 in 8 COVID-19 patients develop #longCOVID symptoms. https://t.co/wechj5flvg https://t.co/pT8lBAWS4g" / X
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet
How swamped preprint servers are blocking bad coronavirus research
Efficacy and effectiveness of inactivated vaccines against symptomatic COVID-19, severe COVID-19, and COVID-19 clinical outcomes in the general population: a systematic review and meta-analysis - The Lancet Regional Health – Western Pacific
Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study - eBioMedicine
For Authors: Submit your work
Congrats to Dr. Therriault and team on their amazing preprint in The Lancet! 👏 🧠 | ALZpath Inc. posted on the topic | LinkedIn
